These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 25935550)

  • 1. High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of International Prognostic Index.
    Kuusisto ME; Haapasaari KM; Turpeenniemi-Hujanen T; Jantunen E; Soini Y; Peroja P; Bloigu R; Karihtala P; Kuittinen O
    J Clin Pathol; 2015 Jul; 68(7):552-6. PubMed ID: 25935550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF-α expression in tumor cells as a novel prognostic marker for diffuse large B-cell lymphoma, not otherwise specified.
    Nakayama S; Yokote T; Hirata Y; Akioka T; Miyoshi T; Hiraoka N; Iwaki K; Takayama A; Nishiwaki U; Masuda Y; Nishimura Y; Tsuji M; Hanafusa T
    Am J Surg Pathol; 2014 Feb; 38(2):228-34. PubMed ID: 24145654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
    Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B
    J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
    Lech-Maranda E; Bienvenu J; Broussais-Guillaumot F; Warzocha K; Michallet AS; Robak T; Coiffier B; Salles G
    Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):131-41. PubMed ID: 20191326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
    Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
    World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal adhesion protein expression in human diffuse large B-cell lymphoma.
    Bosch R; Dieguez-Gonzalez R; Moreno MJ; Gallardo A; Novelli S; Espinosa I; Céspedes MV; Pavón MÁ; Briones J; Grañena A; Sierra J; Mangues R; Casanova I
    Histopathology; 2014 Jul; 65(1):119-31. PubMed ID: 24467224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas.
    Bur H; Haapasaari KM; Turpeenniemi-Hujanen T; Kuittinen O; Auvinen P; Marin K; Koivunen P; Sormunen R; Soini Y; Karihtala P
    Histopathology; 2014 Sep; 65(3):319-27. PubMed ID: 24698430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma.
    Kinnula VL; Lehtonen S; Sormunen R; Kaarteenaho-Wiik R; Kang SW; Rhee SG; Soini Y
    J Pathol; 2002 Mar; 196(3):316-23. PubMed ID: 11857495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma.
    Jang KY; Hwang SH; Kwon KS; Kim KR; Choi HN; Lee NR; Kwak JY; Park BH; Park HS; Chung MJ; Kang MJ; Lee DG; Kim HS; Shim H; Moon WS
    Am J Surg Pathol; 2008 Oct; 32(10):1523-31. PubMed ID: 18724249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF-α receptor 1 expression predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified.
    Nakayama S; Yokote T; Tsuji M; Akioka T; Miyoshi T; Hirata Y; Hiraoka N; Iwaki K; Takayama A; Nishiwaki U; Masuda Y; Nishimura Y; Hanafusa T
    Am J Surg Pathol; 2014 Aug; 38(8):1138-46. PubMed ID: 24805855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of Peroxiredoxin Expression Is Associated with an Aggressive Phenotype in Pancreatic Adenocarcinoma.
    Isohookana J; Haapasaari KM; Soini Y; Karihtala P
    Anticancer Res; 2016 Jan; 36(1):427-33. PubMed ID: 26722077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients.
    Wang J; Zhou M; Zhang QG; Xu J; Lin T; Zhou RF; Li J; Yang YG; Chen B; Ouyang J
    Oncotarget; 2017 Feb; 8(6):9708-9716. PubMed ID: 28039454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
    Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
    Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
    Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Prat J; Sierra J
    Ann Hematol; 2006 Sep; 85(9):597-603. PubMed ID: 16830142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
    Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
    J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Klapper W; Stoecklein H; Zeynalova S; Ott G; Kosari F; Rosenwald A; Loeffler M; Trümper L; Pfreundschuh M; Siebert R;
    Leukemia; 2008 Dec; 22(12):2226-9. PubMed ID: 18754028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary Cutaneous Diffuse Large B-cell Lymphoma has a Higher International Prognostic Index Score and Worse Prognosis Than Diffuse Large B-cell Lymphoma, Leg Type.
    Lee WJ; Won KH; Won CH; Chang SE; Choi JH; Moon KC; Park CS; Huh J; Suh C; Lee MW
    Acta Derm Venereol; 2016 Feb; 96(2):245-50. PubMed ID: 26014205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphoma.
    Mitrovic Z; Ilic I; Nola M; Aurer I; Sonicki Z; Basic-Kinda S; Radman I; Ajdukovic R; Labar B
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):133-7. PubMed ID: 19406723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.